Impact of Periprocedural Hemodiafiltration with Blood Suction from the Right Atrium on the Prevention of Contrast-Induced Acute Kidney Injury

Impact of Periprocedural Hemodiafiltration with Blood Suction from the Right Atrium on the Prevention of Contrast-Induced Acute Kidney Injury - Periprocedural hemodiafiltration with blood suction from the right atrium

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003145

Enrollment

Registered

2010-02-08

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

contrast induced acute kidney injury

Interventions

continuous hemodiafiltration(CHDF) with blood-suction from the right atrium

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with severe renal dysfunction (eGFR <45ml/min) undergoing coronary angiography or percutaneous coronary intervention. (A)age 30 - 90 years old (B)e-GFR <45ml/min (C)Patients undergoing coronary procedure (D)There is no allergy to the contrast medium.

Exclusion criteria

Exclusion criteria: Exclusion criteria were as follows: acute coronary syndrome, cardiogenic shock, congestive heart failure, pregnancy, dehydration, intravascular administration of contrast medium within the previous 7 days, chronic dialysis, and history of allergy to the contrast medium.

Design outcomes

Primary

Measure	Time frame
Development of contrast induced acute kidney injury. Contrast induced acute kidney injury is defined as an increase of serum Cr above 0.3 mg/dL or > 25% within 1 week after exposure to contrast medium.	—

Secondary

Measure	Time frame
Before and after the procedure, we evaluated the serumn and urine markers, such as urinary liver-type fatty acid-binding protein (L-FABP), beta 2-microglobrin (beta2-MG), N-acetyl-beta-D-glucosaminidase (NAG), and serum cystatin C (CysC), beta2-MG, and Creatinine.	—

Countries

Japan

Contacts

Public ContactHiromasa Katoh

Yokohama sakae kyosai hospital internal medicine

045-891-2171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026